359 related articles for article (PubMed ID: 26330419)
1. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.
Kimura T; Kozuma K; Tanabe K; Nakamura S; Yamane M; Muramatsu T; Saito S; Yajima J; Hagiwara N; Mitsudo K; Popma JJ; Serruys PW; Onuma Y; Ying S; Cao S; Staehr P; Cheong WF; Kusano H; Stone GW;
Eur Heart J; 2015 Dec; 36(47):3332-42. PubMed ID: 26330419
[TBL] [Abstract][Full Text] [Related]
2. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
Gao R; Yang Y; Han Y; Huo Y; Chen J; Yu B; Su X; Li L; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Xu B; Popma JJ; Stone GW;
J Am Coll Cardiol; 2015 Dec; 66(21):2298-2309. PubMed ID: 26471805
[TBL] [Abstract][Full Text] [Related]
3. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
[TBL] [Abstract][Full Text] [Related]
4. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y
Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis.
Zhang XL; Zhu L; Wei ZH; Zhu QQ; Qiao JZ; Dai Q; Huang W; Li XH; Xie J; Kang LN; Wang L; Xu B
Ann Intern Med; 2016 Jun; 164(11):752-63. PubMed ID: 27042809
[TBL] [Abstract][Full Text] [Related]
6. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
[TBL] [Abstract][Full Text] [Related]
7. 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial.
Kereiakes DJ; Ellis SG; Metzger C; Caputo RP; Rizik DG; Teirstein PS; Litt MR; Kini A; Kabour A; Marx SO; Popma JJ; McGreevy R; Zhang Z; Simonton C; Stone GW;
J Am Coll Cardiol; 2017 Dec; 70(23):2852-2862. PubMed ID: 29100702
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.
Han Y; Xu B; Fu G; Wang X; Xu K; Jin C; Tao L; Li L; Hou Y; Su X; Fang Q; Chen L; Liu H; Wang B; Yuan Z; Gao C; Zhou S; Sun Z; Zhao Y; Guan C; Stone GW;
JACC Cardiovasc Interv; 2018 Feb; 11(3):260-272. PubMed ID: 29413240
[TBL] [Abstract][Full Text] [Related]
9. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.
Sabaté M; Windecker S; Iñiguez A; Okkels-Jensen L; Cequier A; Brugaletta S; Hofma SH; Räber L; Christiansen EH; Suttorp M; Pilgrim T; Anne van Es G; Sotomi Y; García-García HM; Onuma Y; Serruys PW
Eur Heart J; 2016 Jan; 37(3):229-40. PubMed ID: 26405232
[TBL] [Abstract][Full Text] [Related]
10. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial.
Chevalier B; Onuma Y; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; Smits PC; Kumar R; Wasungu L; Serruys PW
EuroIntervention; 2016 Oct; 12(9):1102-1107. PubMed ID: 27564310
[TBL] [Abstract][Full Text] [Related]
11. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
Stone GW; Ellis SG; Gori T; Metzger DC; Stein B; Erickson M; Torzewski J; Williams J; Lawson W; Broderick TM; Kabour A; Piegari G; Cavendish J; Bertolet B; Choi JW; Marx SO; Généreux P; Kereiakes DJ;
Lancet; 2018 Oct; 392(10157):1530-1540. PubMed ID: 30266412
[TBL] [Abstract][Full Text] [Related]
12. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent - A Randomized Comparison Through 5 Years in Japan.
Kozuma K; Tanabe K; Hamazaki Y; Okamura T; Ando J; Ikari Y; Nakagawa Y; Kusano H; Ediebah D; Kimura T;
Circ J; 2020 Apr; 84(5):733-741. PubMed ID: 32213737
[TBL] [Abstract][Full Text] [Related]
14. Mid- and Long-Term Outcome Comparisons of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis.
Zhang XL; Zhu QQ; Kang LN; Li XL; Xu B
Ann Intern Med; 2017 Nov; 167(9):642-654. PubMed ID: 29049539
[TBL] [Abstract][Full Text] [Related]
15. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
Ali ZA; Serruys PW; Kimura T; Gao R; Ellis SG; Kereiakes DJ; Onuma Y; Simonton C; Zhang Z; Stone GW
Lancet; 2017 Aug; 390(10096):760-772. PubMed ID: 28732815
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial.
Kereiakes DJ; Ellis SG; Metzger DC; Caputo RP; Rizik DG; Teirstein PS; Litt MR; Kini A; Kabour A; Marx SO; Popma JJ; Tan SH; Ediebah DE; Simonton C; Stone GW;
Circulation; 2019 Dec; 140(23):1895-1903. PubMed ID: 31553222
[TBL] [Abstract][Full Text] [Related]
17. Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial.
Xu B; Yang Y; Han Y; Huo Y; Wang L; Qi X; Li J; Chen Y; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Popma JJ; Gao R; Stone GW
EuroIntervention; 2018 Aug; 14(5):e554-e561. PubMed ID: 30082268
[TBL] [Abstract][Full Text] [Related]
18. A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions.
Jabbour RJ; Ielasi A; Tanaka A; Leoncini M; Cortese B; Grigis G; Mitomo S; Regazzoli D; Di Palma G; Rapetto C; Tespili M; Colombo A; Latib A
Cardiovasc Revasc Med; 2017; 18(5S1):S4-S9. PubMed ID: 28314675
[TBL] [Abstract][Full Text] [Related]
19. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
